Literature DB >> 4038056

Pentoxifylline in the treatment of experimental peritonitis in rats.

G E Chalkiadakis, A Kostakis, P E Karayannacos, M E Chalkiadakis, S Sgouromali, H Giamarellou, G D Skalkeas.   

Abstract

The objective of this study was to determine the effect of pentoxifylline on the clinical and pathologic course of experimentally induced peritonitis in rats. This drug is a methyxanthine derivative that has vasodilating properties and may decrease platelet aggregation. Peritonitis was induced in 40 Wistar rats by creating a closed ileal loop 4 cm long 5 cm from the ileocecal valve. The animals were divided into two groups of 20 animals each. The first group served as controls, while each animal of the second group received 17 mg/kg/day of pentoxifylline intramuscularly from the day of operation until 30 days postoperatively. The survival rate was significantly increased in the group receiving pentoxifylline and adhesion or abscess formation was considerably reduced. We concluded that the administration of pentoxifylline prolongs significantly the survival of animals with experimental peritonitis and reduces the development of adhesions and abscesses in the peritoneal cavity. This beneficial effect may be attributed to decreased fibrinogen deposits and increased fibrinolytic activity within the peritoneal cavity, thus rendering the bacteria more susceptible to cellular and noncellular clearing mechanisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038056     DOI: 10.1001/archsurg.1985.01390340039007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  9 in total

1.  Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms.

Authors:  L Ostrosky-Zeichner; J L Soto-Hernandez; V Angeles-Morales; F Teixeira; C Nava-Ruiz; C Rios; F Solis; J Sotelo
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Therapeutic potential for cytokine antagonists: Thalidomide and pentoxifylline in Hansen's disease.

Authors:  T C Peterson
Journal:  Can J Infect Dis       Date:  1995-01

3.  Pentoxifylline modulation of plasma membrane functions in human polymorphonuclear leukocytes.

Authors:  W L Hand; M L Butera; N L King-Thompson; D L Hand
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

4.  Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.

Authors:  X Sáez-Llorens; O Ramilo; M M Mustafa; J Mertsola; C de Alba; E Hansen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

5.  Pentoxifylline inhibits actin polymerization in human neutrophils after stimulation by chemoattractant factor.

Authors:  G Freyburger; F Belloc; M R Boisseau
Journal:  Agents Actions       Date:  1990-08

6.  Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin.

Authors:  P Villa; G Sartor; M Angelini; M Sironi; M Conni; P Gnocchi; A M Isetta; G Grau; W Buurman; L J van Tits
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

7.  Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline.

Authors:  G W Sullivan; H T Carper; W J Novick; G L Mandell
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

8.  Lack of antibacterial activity of pentoxifylline.

Authors:  P K Yu; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

9.  Role of pentoxifylline and sparfloxacin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  Tarek Mohammed Mostafa; Osama Mohamed Ibrahim; Gamal Abd El-Khalek Badra; Mahmoud Samy Abdallah
Journal:  ISRN Gastroenterol       Date:  2014-03-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.